MX2022012938A - Sistema de entrega oral que comprende hidroxicloroquina y/o cloroquina. - Google Patents

Sistema de entrega oral que comprende hidroxicloroquina y/o cloroquina.

Info

Publication number
MX2022012938A
MX2022012938A MX2022012938A MX2022012938A MX2022012938A MX 2022012938 A MX2022012938 A MX 2022012938A MX 2022012938 A MX2022012938 A MX 2022012938A MX 2022012938 A MX2022012938 A MX 2022012938A MX 2022012938 A MX2022012938 A MX 2022012938A
Authority
MX
Mexico
Prior art keywords
day
hydroxychloroquine
chloroquine
delivery system
oral delivery
Prior art date
Application number
MX2022012938A
Other languages
English (en)
Inventor
Nisarg Modi
Fotios M Plakogiannis
Original Assignee
Glanis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glanis Pharmaceuticals Inc filed Critical Glanis Pharmaceuticals Inc
Publication of MX2022012938A publication Critical patent/MX2022012938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Un sistema de administración oral (ODS) del tipo reservorio o emplasto o adhesivo para administrar hidroxicloroquina y/o cloroquina para el tratamiento de artritis reumatoide, lupus eritematoso, SARS CoV-2, porfiria cutánea tardía durante aplicación continua por 1 día, 2 días, 3 días, 4 días, 5 días, 6 días y/o 7 días.
MX2022012938A 2020-04-20 2021-04-19 Sistema de entrega oral que comprende hidroxicloroquina y/o cloroquina. MX2022012938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063012443P 2020-04-20 2020-04-20
PCT/IB2021/000249 WO2021214544A1 (en) 2020-04-20 2021-04-19 Oral delivery system comprising hydroxychloroquine and/or chloroquine

Publications (1)

Publication Number Publication Date
MX2022012938A true MX2022012938A (es) 2023-02-09

Family

ID=78270324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012938A MX2022012938A (es) 2020-04-20 2021-04-19 Sistema de entrega oral que comprende hidroxicloroquina y/o cloroquina.

Country Status (8)

Country Link
US (1) US20230139565A1 (es)
EP (1) EP4138831A4 (es)
JP (1) JP2023520845A (es)
CN (1) CN115427041A (es)
AU (1) AU2021260149A1 (es)
CA (1) CA3175721A1 (es)
MX (1) MX2022012938A (es)
WO (1) WO2021214544A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115068478B (zh) * 2022-07-22 2024-01-09 上海医药工业有限公司 磷酸萘酚喹在制备治疗自身免疫性疾病药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314894A (en) * 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
WO2008006187A2 (en) * 2006-07-12 2008-01-17 Legeev, Yury V. Protein complexes for prevention and treatment of diseases with angiogenesis disorders
AU2011268498A1 (en) * 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent

Also Published As

Publication number Publication date
JP2023520845A (ja) 2023-05-22
WO2021214544A1 (en) 2021-10-28
AU2021260149A1 (en) 2022-09-29
CN115427041A (zh) 2022-12-02
EP4138831A1 (en) 2023-03-01
US20230139565A1 (en) 2023-05-04
EP4138831A4 (en) 2024-05-15
CA3175721A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
ATE546173T1 (de) Überlappende beschichtete stents
MX2022012938A (es) Sistema de entrega oral que comprende hidroxicloroquina y/o cloroquina.
UA86404C2 (ru) Рентгеноконтрастное средство снабжения лекарства
ATE481058T1 (de) Dilatations- und stentablagesystem
IL163573A0 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
HUP0002935A2 (hu) Gyomorban visszatartott, szabályozott hatóanyag kibocsátású mikrogömböcskék javított gyógyszeradagolás elősegítésére
ATE506912T1 (de) Elektroaktive polymer-betätigte hülle für ein implantierbares oder einführbares medizinprodukt
PH12021550611A1 (en) Interleukin 10 Conjugates and Uses Thereof
BR112022012514A2 (pt) Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
HUP9902225A2 (hu) Szilikonalapú, hosszan tartóan androgént adagoló implantátum
GB2401794A (en) Bone plates
NZ760204A (en) Hypolipidemic effects of bacillus coagulans
BR0315139A (pt) Agentes antibacterianos de tetraidroquinolina tricìclica
SG10201901275PA (en) Storage device and server including the storage device
MX2021014189A (es) Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.
EP4117555A4 (en) ORTHOPEDIC IMPLANTS AND INSTRUMENTS FOR THEIR INSTALLATION
TNSN08537A1 (fr) Precurseurs de medicaments du type peneme
MX2022012841A (es) Sistema de entrega transdérmica y/o tópica que comprende hidroxicloroquina y/o cloroquina.
MX2020012543A (es) Diltiazem para usarse en el tratamiento de infecciones microbianas.
PH12021551152A1 (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
BRPI0608326A2 (pt) suporte de exoesqueleto para colocação de uma fita de tratamento dental
BRPI0210317C1 (pt) complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos
MX2021005158A (es) Portador y protector de la mucosa bucal.
MX2020007627A (es) Uso de la carrimicina o de sus ingredientes activos.
EP4219703A3 (en) Treatment of a condition associated with infection with an oncogenic bacterium